Structural basis for urate recognition and apigenin inhibition of human GLUT9.
Zilin ShenLi XuTong WuHuan WangQifan WangXiaofei GeFang KongGaoxingyu HuangXiaojing PanPublished in: Nature communications (2024)
Urate, the physiological form of uric acid and a potent antioxidant in serum, plays a pivotal role in scavenging reactive oxygen species. Yet excessive accumulation of urate, known as hyperuricemia, is the primary risk factor for the development of gout. The high-capacity urate transporter GLUT9 represents a promising target for gout treatment. Here, we present cryo-electron microscopy structures of human GLUT9 in complex with urate or its inhibitor apigenin at overall resolutions of 3.5 Å and 3.3 Å, respectively. In both structures, GLUT9 exhibits an inward open conformation, wherein the substrate binding pocket faces the intracellular side. These structures unveil the molecular basis for GLUT9's substrate preference of urate over glucose, and show that apigenin acts as a competitive inhibitor by occupying the substrate binding site. Our findings provide critical information for the development of specific inhibitors targeting GLUT9 as potential therapeutics for gout and hyperuricemia.
Keyphrases
- uric acid
- structural basis
- metabolic syndrome
- electron microscopy
- endothelial cells
- reactive oxygen species
- high resolution
- type diabetes
- oxidative stress
- minimally invasive
- anti inflammatory
- amino acid
- risk assessment
- weight gain
- skeletal muscle
- adipose tissue
- body mass index
- health information
- weight loss
- combination therapy
- cancer therapy